Sodium channel protein type 3 subunit alpha (SCN3A)
Homo sapiens — UniProt Q9NY46
Data last refreshed: (UniProt release unknown)
Key facts
Sodium channel protein type 3 subunit alpha (SCN3A) is a protein from Homo sapiens identified by UniProt accession Q9NY46, 2000 residues long. MolForge cross-references it against 7 known binders and 474 disease associations.
- UniProt accession: Q9NY46; gene symbol SCN3A.
- Organism: Homo sapiens.
- Length: 2000 amino acids.
- Approved drugs acting on it (DrugCentral): Cannabidiol, Lidocaine, Lamotrigine, Benzocaine and Mepivacaine and others.
- Top disease associations (Open Targets): developmental and epileptic encephalopathy, 62, partial epilepsy and epilepsy.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Sodium channel protein type 3 subunit alpha |
|---|---|
| UniProt accession | Q9NY46 |
| Gene | SCN3A |
| Organism | Homo sapiens |
| Length | 2000 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (7)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (474)
Diseases linked to this target (Open Targets).
- developmental and epileptic encephalopathy, 62 · score 0.74
- partial epilepsy · score 0.74
- epilepsy · score 0.70
- developmental and epileptic encephalopathy · score 0.65
- familial focal epilepsy with variable foci · score 0.65
- Seizure · score 0.64
- bipolar disorder · score 0.63
- pain · score 0.61
- migraine disorder · score 0.60
- atrial fibrillation · score 0.60
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9NY46-F1 | alphafold | PREDICTED | 68.28 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9NY46.
Amino-acid sequence (2000 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target SCN3A?
DrugCentral lists 7 approved drugs whose mechanism of action is SCN3A: Cannabidiol, Lidocaine, Lamotrigine, Benzocaine, Mepivacaine, Phenytoin and Ropivacaine.
Which diseases are associated with SCN3A?
The strongest Open Targets associations for SCN3A are developmental and epileptic encephalopathy, 62, partial epilepsy, epilepsy, developmental and epileptic encephalopathy and familial focal epilepsy with variable foci.
How long is the SCN3A protein?
The Homo sapiens SCN3A protein (UniProt Q9NY46) is 2000 amino acids long.
Browse: Targets: S · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9NY46 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9NY46 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.